Investigational drug · Phase 2
SCI-110
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Tourette Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SCI-110"
First trial start
2026
Jun 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCI-110", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tourette Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "SCI-110" as an intervention, largest first.
- SCI-110 in the Treatment of Tourette SyndromePivotal-lookingNot yet recruiting
Neurothera Labs Inc.Industry
NCT05126888 · 164 participants (planned) · Start Jun 2026 · Primary completion Oct 2027
Drug: SCI-110 · For: Tourette Syndrome
Sites: New Haven, Connecticut; Hanover, Germany; Tel Aviv, Israel
- SCI-110 for Alzheimer Disease and AgitationStatus unknown
The Israeli Medical Center for Alzheimer'sAcademic, hospital or other
NCT05239390 · 20 participants (planned) · Start Dec 29, 2021 · Primary completion Jun 29, 2023
Drug: SCI -110 · For: Alzheimer Disease
Sites: Ramat Gan, Israel
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Tourette Syndrome
- Ecopipam HydrochloridePhase 32 trials
Emalex Biosciences Inc. · Tourette Syndrome, Tourette Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.